Accessibility Menu
LivaNova Plc logo

LivaNova Plc(NASDAQ) LIVN

Market Cap$4.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1993)+575%
5 Year-7%
1 Year+90%
1 Month-3%
$80.27
-0.96%
-0.78Today
After hours$80.18-$0.09 (-0.11%)
LivaNova Plc last closing stock price
MetricPriceDate
Last closeUSD 80.142026-07-31
LivaNova Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.49%USD 78.192026-07-24
1 month-2.84%USD 82.482026-07-01
3 month+31.38%USD 61.002026-05-01
Year to date+30.25%USD 61.532025-12-31
1 year+89.95%USD 42.192025-07-31
3 year+36.85%USD 58.562023-08-01
5 year-7.14%USD 86.302021-07-30
Since inception+575.42%USD 12.001993-02-11

LivaNova Plc Financials at a Glance

Market Cap

$4.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.43B

Net Income (TTM)

$107.14M

EPS (TTM)

$1.94

P/E Ratio

41.84

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$80.27

Volume

514,696.109

Open

$80.56

Previous Close

$80.14

Daily Range

$79.29 - $81.78

52-Week Range

$41.02 - $85.27

Estimated Earnings Date

Aug 5, 2026

LIVN: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About LivaNova Plc

LivaNova makes tools that help doctors treat heart and brain problems. Their devices help people with epilepsy or depression manage their health. They also make machines that support breathing during major surgeries.

Devices That Help People

  • Cardiopulmonary Systems: Heart-lung machines and monitors used during surgery; generated $208.7 million in net revenue in Q1 2026.
  • Neuromodulation Therapy: Implanted devices that treat epilepsy and depression; generated $151.8 million in net revenue in Q1 2026.
  • Circulatory Support: Temporary machines that help patients whose heart or lungs are failing.
  • Sleep Apnea Products: Nerve stimulators designed to keep airways open while patients sleep.

Recent Strategic Milestones

  • Repaid $95.9 million in debt early in January 2026 to settle its term facilities.
  • Earned premarket approval from the FDA for its aura6000 sleep apnea system in March 2026.
  • Partnered with Verily to find physical signs of depression using clinical biomarkers.
  • Introduced the Essenz Perfusion System to help doctors monitor patients during heart bypass procedures.

How LivaNova Operates

The company maintains a global sales network that serves specialized physicians and hospitals in the United States, Europe, and international markets. It uses sensing technology to provide real-time data to help medical teams during complex heart operations.

The Q1 2026 Scorecard

  • Net revenue reached $362.3 million in Q1 2026, up 14.3% from Q1 2025.
  • Net income turned positive at $22.3 million in Q1 2026, improved from a $327.3 million loss the previous year.
  • Operating cash flow was $15.2 million in Q1 2026, down 36.5% compared to Q1 2025.
  • Free cash flow hit $926,000 in Q1 2026, down 93% from $13.2 million year-over-year.

The Big Picture

LivaNova has evolved into a focused medical device company targeting specialized heart and brain therapies. Its expansion into sleep treatments and debt reduction efforts define its current path.

AI Generated • May 22, 2026

Industry

Healthcare Equipment and Supplies

Employees

3,300

CEO

Vladimir A. Makatsaria, MBA

Headquarters

London, GL W2 6LG, GB

LIVN Financials

Key Financial Metrics (TTM)

Gross Margin

67.57%

Operating Margin

14.16%

Net Income Margin

7.47%

Return on Equity

9.13%

Return on Capital

11.92%

Return on Assets

4.26%

Earnings Yield

2.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

54.93M

Volume

514.70K

Avg. Volume

756.29K

Financials (TTM)

Gross Profit

$968.51M

Operating Income

$202.99M

EBITDA

$215.65M

Operating Cash Flow

$245.59M

Capital Expenditure

-$84.52M

Free Cash Flow

$161.08M

Cash & ST Invst.

$539.70M

Total Debt

$334.50M

LivaNova Plc Performance Analysis

LivaNova Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,021,805,000-1.3%
20232023-12-31USD 1,153,545,00012.9%
20242024-12-31USD 1,253,437,0008.7%
20252025-12-31USD 1,388,053,00010.7%
LivaNova Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.3%
Q32025-09-301.5%
Q42025-12-310.9%
Q12026-03-310.4%
LivaNova Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.61-39.9%
20232023-12-31USD 0.32N/A
20242024-12-31USD 1.16258.0%
20252025-12-31USD -4.45N/A
LivaNova Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30108.3%
Q32025-09-30-2.0%
Q42025-12-3116.3%
Q12026-03-31-29.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$362.26M

+14.3%

Gross Profit

$244.85M

+10.9%

Gross Margin

67.59%

N/A

Market Cap

$4.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.35M

N/A

Employees

3,300

N/A

Net Income

$22.30M

+106.8%

EBITDA

$50.52M

+117.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$539.70M

-26.9%

Total Debt

$334.50M

-50.7%

Accounts Receivable

$229.30M

-0.9%

Inventory

$165.50M

+7.5%

Long Term Debt

$331.90M

-43.7%

Short Term Debt

$2.60M

-97.1%

Return on Assets

4.26%

N/A

Return on Invested Capital

11.57%

N/A

Free Cash Flow

$926.00K

-93.0%

Operating Cash Flow

$15.22M

-36.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LEGNLegend Biotech Corporation
$18.55-2.62%
IDYAIDEAYA Biosciences, Inc.
$35.50-2.47%
CDTXCidara Therapeutics, Inc.
$221.38+0.00%
SRRKScholar Rock Holding Corporation
$47.30-3.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About LIVN

What is the current price of LivaNova Plc?

LivaNova Plc is trading at $80.14 per share.

What is the 52-week range for LivaNova Plc?

Over the past 52 weeks, LivaNova Plc has traded between $41.02 and $85.27.

How much debt does LivaNova Plc have?

As of the most recent reporting period, LivaNova Plc reported total debt of $343.44M.

How much cash does LivaNova Plc have on hand?

LivaNova Plc reported $539.71M in cash and cash equivalents in its most recent financial results.

What is LivaNova Plc’s dividend yield?

LivaNova Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.